GATAD2A

Across TCGA pan-cancer cohorts, GATAD2A mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of GATAD2A’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where GATAD2A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GATAD2A is over-expressed in tumor.

COAD, LUAD, and LSCC are the cancer types where GATAD2A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GATAD2A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	All	+0.330	<.001	9	view →
LUAD	Male	III,IV	+0.282	<.001	9	view →
LSCC	Male	II,III,IV	+0.415	<.001	8	view →
HNSC	Male	All	+0.165	<.001	7	view →
PDAC	Female	II,III,IV	+0.343	<.001	5	view →
CCRCC	Male	All	+0.091	<.001	4	view →
OV	All	All	+0.283	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

GATAD2A–COAD

Open the COAD breakdown →